Anesthetic Implications of End-Stage Liver Disease and Liver Transplantation Todd M. Oravitz, MD Associate Professor Department of Anesthesiology University of Pittsburgh School of Medicine Chief, Liver Transplantation Anesthesia VA Pittsburgh Healthcare System Lecture objectives 1) Discuss the pathophysiology of end-stage liver disease 2) Discuss the management of anesthesia in patients with end-stage liver disease 3) Discuss the perioperative management of patients undergoing liver transplantation 4) Discuss the perioperative management of patients undergoing procedures after liver transplantation Normal Hepatic Function • Liver plays a role in – Carbohydrate metabolism • Produces/stores glycogen, which can be depleted after 24-48 hours of fasting • Site of gluconeogenesis, with amino acids, glycerol and lactate as substrates Normal Hepatic Function • Liver plays a role in – Protein metabolism • All plasma proteins, except for immunoglobulins, made in the liver – Albumin helps maintain plasma oncotic pressure and is the primary binding/transport protein for many anesthetic drugs • All coagulation factors, except for factor VIII and von Willebrand factor, made in the liver Normal Hepatic Function • Liver plays a role in – Drug metabolism • Most medications undergo at least some hepatic degradation or biotransformation, or both • End products either metabolically inactive or more water-soluble for biliary or urinary excretion Normal Hepatic Function • Drug metabolism – Phase I reactions • Include oxidation/reduction (redox) • Cytochrome p450 • Benzodiazepines and barbiturates degraded via phase I – Phase II reactions • May or may not follow phase I • Involve conjugation to facilitate elimination via bile or urine Normal Hepatic Function • Drug metabolism – Cytochrome p450 • Ethanol, ketamine capable of enzyme induction, resulting in tolerance to the drugs’ effects • Cimetidine, chloramphenicol can cause prolongation of drug effects by enzyme inhibition Normal Hepatic Function • Anatomy/physiology – Largest organ in the body, weighing about 1.5kg – Right upper quadrant location – Dual blood supply • Liver blood flow ~1.5L/min • Hepatic artery • Portal vein Normal Hepatic Function • Dual blood supply – Hepatic artery • Accounts for 25% of blood flow and 50% of O2 delivery • Flow is auto-regulated – Portal vein • Accounts for 75% of blood flow and 50% of O2 delivery • Flow depends on GI and splenic blood flow End-Stage Liver Disease (ESLD) • The liver has a remarkable capacity for regeneration • The liver has tremendous physiologic reserve • Hepatic disease can develop insidiously and a large proportion of function can be lost before problems become apparent End-Stage Liver Disease (ESLD) • Common symptoms – Anorexia – Weakness – Nausea/vomiting – Abdominal pain • Common signs – Hepatosplenomegaly – Ascites – Jaundice – Spider angiomas – Encephalopathy Pathophysiology of ESLD • Hepatic changes – Portal hypertension – high resistance to blood flow through the liver – hallmark of ESLD – Leads to accumulation of blood and increased venous pressure in the vascular beds “upstream” to the liver • Esophagus • Spleen • Stomach and intestines Pathophysiology of ESLD • Portal hypertension leads or contributes to – Ascites – Esophageal varices – Gastric and other intra-abdominal varices – Splenomegaly Pathophysiology of ESLD • Esophageal varices – Portal-systemic collaterals that allow splanchnic venous blood to flow from the high-pressure portal system to the low-pressure azygos and hemi-azygous system – Not all patients with ESLD develop varices and not all patients with varices have bleeding – Patients that do bleed have significant morbidity and mortality – up to 30% of initial episodes of bleeding are fatal Variceal Disease • Treatment – Chronic • Propranolol is a non-selective beta-blocker that decreases portal venous pressure – Reduces risk of primary bleeding – Reduces risk of re-bleed • Banding, ligation, sclerotherapy • Transjugular intrahepatic portosystemic shunt (TIPS) Pathophysiology of ESLD • TIPS – Improves blood flow through the liver – Percutaneous approach to create a shunt between the portal and hepatic veins – Decreases activity of the sodium-retaining pathways – Improves renal response to diuretics TIPS Variceal Disease • Treatment – Acute • • • • • • Aggressive fluid resuscitation; ± blood Correct coagulation defects, if present Airway protection – intubation Octreotide – reduces portal pressure Endoscopy with possible intervention – banding Balloon tamponade – Blakemore tube Pathophysiology of ESLD • Hepatic changes – Spontaneous bacterial peritonitis (SBP) • Spontaneous infection of ascitic fluid without an intra-abdominal source • Increased intestinal wall permeability allows translocation of bacterial into the conducive media of ascitic fluid Pathophysiology of ESLD • Hepatic changes – Spontaneous bacterial peritonitis (SBP) • Cefotaxime is the antibiotic of choice for treatment as it covers 95% of the offending flora, including the 3 most common – E coli, Klebsiella and pneumococcus • Quinolone (e.g. ciprofloxacin) prophylaxis is indicated after an initial episode as there is a 70% recurrence rate in the 1st year and it has a beneficial effect on patient survival • Two year survival after SBP is less than 50% Pathophysiology of ESLD • Hepatic changes – Hepatic encephalopathy (HE) • Occurs when substances normally metabolized by the liver accumulate due to its dysfunction – Ammonia felt to be most important in HE patients • Increased activity of inhibitory neurotransmitters also may play a role – Increased GABAergic tone – Administration of the benzodiazepine antagonist flumazenil often results in an improvement in the mental status of HE patients Hepatic Encephalopathy • Often occurs after a precipitating event – Increased ammonia level • Large dietary protein load • GI bleeding • Azotemia – Decreased hepatic perfusion • Anesthesia and surgery with resultant hypotension, hypoxemia and/or hypovolemia • Diuretic administration, paracentesis or GI disturbance such as diarrhea or vomiting Hepatic Encephalopathy • Other possible precipitating events – Sepsis • Increased ammonia levels due to protein catabolism • Decreased hepatic perfusion – Creation of portal-systemic shunt • TIPS • Results in decreased hepatic metabolism Hepatic Encephalopathy • Treatment – Remove/minimize, to the extent possible, any/all underlying causes – Decrease blood ammonia levels • Reduce production – Lower dietary protein intake – Neomycin – targets urease-producing bacteria • Reduce GI absorption – Lactulose – non-absorbable disaccharide that decreases large intestinal absorption of ammonia and also promotes growth of non-urease producing bacteria Pathophysiology of ESLD • Coagulation/hematologic changes – Coagulopathy results mostly from two factors • Impaired synthesis of clotting factors • Thrombocytopenia – Decreased levels of anticoagulants, most notably antithrombin III and protein C, can lead to thrombotic complications • Portal vein thrombosis • Deep venous thrombosis (DVT) • Pulmonary embolism (PE) Coagulation/Hematologic Changes • Coagulopathy – Impaired synthesis of coagulation cascade proteins • All clotting factors, except von Willebrand factor, made in the liver • Vitamin K dependent factors – II, VII, IX and X – at additional risk – Bile salts needed for intestinal absorption of vitamin K and may be decreased by ESLD – Overall poor nutritional status in many ESLD patients Coagulation/Hematologic Changes • Coagulopathy – Thrombocytopenia • Portal hypertension-induced splenomegaly – Occurs in 30-60% of ESLD patients – Up to 90% of platelets can be sequestered in the enlarged spleen – Platelet count usually >30K and spontaneous bleeding is fairly uncommon • Associated disease processes can contribute – Poor nutrition – folate deficiency – Chronic alcohol intake Pathophysiology of ESLD • Cardiovascular changes – Hyperdynamic circulation • • • • • Increased cardiac output Decreased systemic vascular resistance Normal to decreased blood pressure Increased heart rate Normal to increased stroke volume Pathophysiology of ESLD blood pressure=cardiac output x systemic vascular resistance ↔/↓BP = ↑CO X ↓SVR ↓ −−−−−−−−−−−−−−−−− ↓ ↓ ↑HR X ↔/↑SV cardiac output = heart rate x stroke volume Pathophysiology of ESLD • Cardiovascular changes – Result from development of vasodilation and abnormal shunting • Blood passes from the arterial to the venous circulation without crossing a capillary bed; an anatomic example of this is a spider angioma • Thought to result from increased plasma levels of glucagon and vasoactive intestinal polypeptide Pathophysiology of ESLD • Pulmonary changes – Hypoxemia, with PaO2 values of 60-70mmHg, is commonly seen in ESLD patients – Causes include • • • • Underlying cardiopulmonary disease Intrapulmonary shunting V/Q mismatch Decreased diffusion capacity Pulmonary Changes - Hypoxemia • Underlying cardiopulmonary disease – Congestive heart failure, interstitial lung disease, chronic obstructive pulmonary disease • Intrapulmonary shunting – Pre-capillary or larger arteriovenous communications are the result of intrapulmonary vascular dilatation – Hepatopulmonary syndrome Hepatopulmonary Syndrome (HPS) • Defined by the clinical triad of – Chronic liver disease – Increased A-a gradient – Evidence of intrapulmonary vascular dilatation • Increased pulmonary nitric oxide production is the likely cause • Usually diagnosed by echocardiography Hepatopulmonary Syndrome (HPS) • Incidence 5-30% • Decreased survival compared to patients with similar degree of liver disease who do not have HPS • HPS patients with severe preoperative hypoxemia (PaO2 <50mmHg) have increased mortality after liver transplantation • HPS often resolves completely after transplant Pathophysiology of ESLD • Pulmonary changes – Hepatic hydrothorax • Seen in 5-10% of ESLD patients • Pleural effusion from transfer of ascitic fluid through diaphragmatic defects • Treated by sodium restriction, diuretics and/or thoracentesis Pathophysiology of ESLD • Pulmonary changes – Pulmonary hypertension • Seen in <5% of ESLD patients • Defined as mean pulmonary artery pressure (MPAP) >25mmHg and increased pulmonary vascular resistance – Patients with MPAP >35mmHg have increased perioperative morbidity/mortality – Patients with MPAP >50mmHg, at VAPHS, are not transplant candidates secondary to greatly increased mortality • Etiology not well understood Pulmonary Hypertension • Avoid physiologic conditions that increase pulmonary vascular resistance, as acute right-sided heart failure can result – Hypoxemia – Hypercapnia – Acidosis • Important to remember during monitored anesthesia care (MAC) cases Pathophysiology of ESLD • Renal changes – Impaired free water and sodium excretion – Decreased renal perfusion and glomerular filtration rate (GFR) – Vasodilation, which effectively reduces plasma volume, leads to sympathetic nervous system activation of the renin-angiotension-aldosterone pathway, resulting in enhanced sodium and free water resorption Pathophysiology of ESLD • Renal changes lead to development of – Edema – Ascites • Long term decrease in renal perfusion and GFR can lead to hepatorenal syndrome (HRS) – HRS occurs in up to 10% of patients with ESLD – Functionally HRS is a pre-renal phenomenon whose hallmark is intense renal vasoconstriction Hepatorenal Syndrome (HRS) • Type I – Progressive oliguria with rapidly rising creatinine – Often follows an episode of spontaneous bacterial peritonitis (SBP) – Poor outcome – median survival < 1 month without intervention – Treatment with albumin, octreotide, and midodrine has shown some promise Hepatorenal Syndrome (HRS) • Type II – Usually seen in patients with refractory ascites – Renal impairment is usually more mild than type I – Clinical course is far less progressive than type I Pathophysiology of ESLD • Ascites – Common complication of ESLD; in fact, nearly 50% of patients develop ascites within 10 years of initial diagnosis – Significant associated mortality – nearly 50% of patients die within 3 years of onset of ascites – Etiology complex, multifactorial and not completely understood • Portal hypertension • Sodium, water retention Pathophysiology of ESLD • Ascites – Treatment • Sodium restriction and diuretics (spironolactone) • Refractory cases treated with repeated large-volume paracentesis and volume expanders, usually albumin • Transjugular intrahepatic portosystemic shunt (TIPS) also can be used for refractory ascites, but it has not been shown to improve survival compared to repeat paracentesis Anesthesia and ESLD • Preoperative preparation should focus on optimizing liver-related pathology (if possible) – Volume status – Coagulation – parenteral vitamin K if INR elevated – Renal function – Electrolyte imbalance – Nutritional status Anesthesia and ESLD • Medications should be scrutinized in the preoperative period, as there are a large number that can cause or worsen underlying hepatic dysfunction – Acetaminophen – Isoniazid – Methyldopa – Phenytoin – Indomethacin Anesthesia and ESLD • Administration of anesthesia decreases liver blood flow via changes in hepatic perfusion pressure and/or splanchnic vascular resistance • Physiologic reserve is decreased patients with ESLD • Perioperative morbidity and mortality in patients undergoing all but minor procedures is increased Child-Pugh Classification System Child-Pugh Class and Mortality • Thirty day mortality in patients undergoing either cholecystectomy, hernia repair, GI or miscellaneous surgery; 25% were emergencies – Class A – 10% – Class B – 30% – Class C – 80% • Highest mortality in GI and emergent procedures Child-Pugh Class and Mortality • Three month mortality for patients hospitalized with liver complications, but not undergoing surgery – Class A – 4% – Class B – 14% – Class C – 50% Model for End-Stage Liver Disease (MELD) Score • Originally developed to predict survival in patients with portal hypertension undergoing elective TIPS procedures • Found to be an accurate predictor of survival in patients with a variety of liver diseases • Adopted in 2002 as the rank list criteria for liver transplantation by the United Network of Organ Sharing (UNOS), replacing Child-Pugh Model for End-Stage Liver Disease (MELD) Score • Resulted in an almost 15% reduction in mortality on the waiting list • Median waiting time also decreased, about 35%, from 656 to 416 days • While it accurately estimates mortality on the waiting list, MELD does not correlate well with mortality following liver transplantation MELD Score Anesthesia and ESLD • Perioperative mortality calculator – http://www.mayoclinic.org/medicalprofessionals/model-end-stage-liver-disease/postoperative-mortality-risk-patients-cirrhosis – Input patient age, ASA physical status, bilirubin, creatinine, INR and cirrhosis etiology (alcoholic/cholestatic vs viral/other) – Calculates mortality at 7, 30 and 90 days, as well as 1 and 5 years Anesthesia and ESLD • 52 year male presenting for R total knee arthroplasty – PMHx HTN, DM, hep C, CKD, COPD, GERD, PTSD – Lab data – HgB 11, platelets 95K, K 4, BUN/Cr 20/1.4, total bili 1.5, PT/INR 15.7/1.3 • Does this patient have a significant degree of morbidity/mortality in the perioperative period? Anesthesia and ESLD • YES!!! – 7 day mortality – 30 day mortality – 90 day mortality – 1 year mortality – 5 year mortality 2.719% 10.696% 16.698% 29.079% 61.382% Anesthesia and ESLD • Pharmacokinetic and pharmacodynamic considerations – Multiple aspects possibly affected • • • • Hepatic metabolism Renal metabolism Volume of distribution Protein binding – All medications should be titrated to effect • “You can always give more” Anesthesia and ESLD • Intraoperative management – Anesthetic technique • No one medication, technique or approach has proven superior in patients with ESLD • MAC and regional are appropriate, but need to be considered on a case-by-case basis – All medications should be titrated to effect Intraoperative Management • Overall hepatic blood flow is decreased due to portal hypertension – Hepatic oxygenation, therefore, is more dependent on hepatic artery blood flow than normal – Volatile anesthetics blunt the ability of the hepatic artery to vasodilate in the face of decreased portal vein blood flow Intraoperative Management • Overall hepatic blood flow is decreased due to portal hypertension – Any decrease in systemic blood pressure, for example from volatile anesthetic-induced peripheral vasodilation, can decrease hepatic artery blood flow • Probably best to avoid delivering high concentrations of volatile agents to patients with ESLD Intraoperative Management • Monitoring and vascular access – Standard American Society of Anesthesiology (ASA) monitors – Additional invasive monitors as dictated by • Degree of liver disease • Presence/absence of other underlying disease • Nature of surgical procedure Intraoperative Management • Monitoring and vascular access – Other considerations • • • • Urine output “Gentle” esophageal manipulation – varices Bispectral index (BIS) Real-time coagulation assessment – thromboelastography (TEG) – Vascular access • Large bore catheter(s) recommended Intraoperative Management • Induction of general anesthesia (GA) – Rapid sequence vs routine induction – Does the presence of ascites = full stomach? – Succinylcholine may have a prolonged duration of action due to decreased plasma cholinesterase activity – Theoretically may need larger initial dose of non-depolarizing muscle relaxants due to increased volume of distribution, especially in those patients with significant ascites Intraoperative Management • Maintenance of GA – The golden rule – maintain homeostasis • • • • • Avoid hypotension Avoid low cardiac output Avoid bradycardia Avoid myocardial depression Avoid peripheral vasodilation – Remember, pressure = flow X resistance (BP = CO X SVR) Intraoperative Management • Maintenance of GA – Halothane hepatitis • • • • Diagnosis of exclusion Autoimmune vs hepato-toxic metabolites ~1:35,000 incidence of fatal hepatic necrosis Risk factors – – – – Middle age Obesity Female gender Repeated exposure, especially within 28 days Intraoperative Management • Maintenance of GA – Muscle relaxants • Metabolism of both rocuronium and vecuronium is 60-90% dependent on hepatic degradation and biliary excretion • Pancuronium relies mostly on renal excretion (80%) but about 20% of metabolism occurs via the liver • Cisatracurium, by nature of its organ-independent clearance via Hofmann degradation, is ideal to use in patients with ESLD Intraoperative Management • Maintenance of GA – Fluid therapy • No prospective data exist showing a benefit to crystalloid vs colloid • Maintenance of adequate filling pressure is more important than the choice of fluid – Blood transfusion • Communication with blood bank is crucial • RBCs, FFP, platelets, cryoprecipitate Intraoperative Management • Vasoactive medications – ESLD patients typically are in a hyperdynamic, vasodilated state – Anesthetic-induced increases in peripheral vasodilation can lead to profound hypotension – Administration of vasoconstricting agents – phenylephrine, norepinephrine, vasopressin – is common and dosing is often higher than normally required Intraoperative Management • Blood transfusion – Lab turnover time may render traditional coagulation testing (i.e. PT/INR, PTT, platelet count) irrelevant during high-volume blood loss cases in ESLD patients – Thromboelastography (TEG) • Allows real-time assessment of all aspects of the coagulation cascade • Used in cardiac surgery, trauma and liver transplantation Thromboelastography (TEG) Thromboelastography (TEG) • Components – R, reaction time: time until initial clot formation – K, clot formation time: period after R to achieve clot width of 20mm – α, alpha angle: measures speed of clot formation – MA, maximum amplitude: measure of the strength of the fully formed clot – A60/MA ratio: compares maximum clot size to that 60 minutes later Thromboelastography (TEG) • Treatment decisions – Prolongation of R and/or K, or a decrease in α, treated with fresh frozen plasma (FFP) – Decrease in MA treated with platelets – A60/MA < 0.85 indicates fibrinolysis and is treated with epsilon-aminocaproic acid • Use of TEG during liver transplantation has been shown to reduce the amounts of RBCs and FFP transfused Orthotopic Liver Transplantation (OLTx) • VA Pittsburgh Healthcare System experience – Started doing liver transplants in the mid-1980s – Dedicated VA transplant surgeon since Jan 2004 – One year survival 84.6%; national average 90.2% • Latest data per UNOS • Period ending December 31, 2012 OLTx at VAPHS • • • • Cases are always emergent All adult patients Frequently occur after hours or on weekends Separate, dedicated call team – Anesthesiologist – CRNA – Anesthesia technician OLTx at VAPHS Common ESLD etiologies Uncommon etiologies • Hepatitis C • Alcoholic cirrhosis • Hepatocellular carcinoma (HCC) • Some combination of the three • Primary sclerosing cholangitis • Primary biliary cirrhosis • Non-alcoholic steatohepatitis (NASH) • Autoimmune hepatitis OLTx at VAPHS • Preoperative considerations – All patients undergoing multi-disciplinary evaluation, including surgery, anesthesiology and psychiatry consultation – Workup includes a full battery of lab tests, ECG, CXR and PFTs Preoperative Considerations • Cardiopulmonary workup includes – Stress testing • Low threshold for cardiac catheterization • Case-by-case decision, but generally any patient with more than mild CAD is not a surgical candidate – Transthoracic echocardiography • Pulmonary artery pressure (PAP) estimation • Mean PAP >35mmHg associated with increased perioperative morbidity/mortality; patients with MPAP >50mmHg are not surgical candidates OLTx at VAPHS • Intraoperative considerations – Standard ASA monitors plus • BIS • Arterial line – right femoral • Large-bore iv access – “double stick” – Right internal jugular (RIJ) 9Fr double-lumen introducer with pulmonary artery catheter (PAC) – RIJ veno-venobypass (VVB) cannula, 18Fr – Ultrasound guidance • Pacing/defibrillator pads OLTx at VAPHS • Intraoperative considerations – Emergency case – “full stomach” management – Anesthetic maintenance • Usually a balanced technique • My preference is more toward a cardiac anesthetic – High dose benzodiazepine/opioid dosing – Low, steady state dose of volatile anesthetic – Muscle relaxant – dealer’s choice Intraoperative Considerations • Coagulation management – Arterial blood gas (ABG) and TEG done hourly – PT/INR/PTT/platelets done every 2 or 3 hours – Reperfusion resets the lab timeline – Additional labs as needed Intraoperative Considerations • Rapid infusion system (RIS) – In OR and primed for every case – Decision to use made on a case-by-case basis • Cell-saver blood salvage system – Set up for every case – Not employed until after reperfusion in VAPHS patients with hepatocellular CA Intraoperative Considerations • OLTx procedure can be broken down into 3 phases – Pre-anhepatic – Anhepatic – Post-anhepatic or neohepatic • Average operative time at VAPHS ~8 hours Pre-anhepatic Phase • Lasts from skin incision to the point when the native liver is freed to its vascular pedicle • Native liver is mobilized – Hilum located – Hepatic artery (HA) ligated – Bile duct transected – Infra- and supra-hepatic inferior vena cava (IVC) and portal vein (PV) encircled Pre-anhepatic Phase • May involve veno-venobypass (VVB) – Venous outflow via 2 cannulas – L common iliac vein and portal vein – Venous return via 1 cannula – R internal jugular (may use the L axillary vein via cutdown) • VVB complications include – Hypothermia – Air or thromboembolism – Brachial plexus and/or vessel trauma Anhepatic Phase • Lasts from clamping of the infra- and suprahepatic IVC, PV and hepatic artery and ends when the IVC and PV anastomoses are complete • Usually see decreased cardiac output/index from decreased venous return • Use of VVB can lead to profound hypothermia, especially if a heat exchanger is not used Anhepatic Phase • Portal hypertension does NOT protect against hemodynamic instability • Anastomotic order – Supra-hepatic IVC – Infra-hepatic IVC – Portal vein – Hepatic artery Anhepatic Phase • Reperfusion – Occurs when PV (inflow) and IVC (outflow) anastomoses are complete – Often associated with hemodynamic instability • Bradycardia, asystole • Hypotension • Hyperkalemia, despite donor organ flush, may result from preservation solution with high K+ concentration • Air or thromboembolism • Pulmonary hypertension, often with acute right heart failure, is rare but may occur Anhepatic Phase • Reperfusion – Post-reperfusion syndrome • Decrease in mean arterial pressure of at least 30% for at least 1 minute within 5 minutes of reperfusion • Usually see bradycardia, high filling pressures and peripheral vasodilation (↓ SVR) • Washout of “evil humors” from the donor organ – kinins, cytokines, free radicals • Usually responds to vasoconstrictors – phenylephrine, norepi or vasopressin Anhepatic Phase • Reperfusion – Preparation should include • Ventilation with 100% FiO2 • Priming/filling of the RIS, if in use • Vasoactive meds/infusions in line – Epinephrine – Calcium – Phenylephrine, norepi, vasopressin • Pacer connected, turned on Post-anhepatic (Neohepatic) Phase • Begins with PV and HA unclamping • Biliary drainage is reconstructed – End-to-end anastomosis, often with T-tube – Roux-en-Y choledochojejunostomy • Fibrinolysis may occur – epsilon-aminocaproic acid 500mg-1g iv if present on TEG • Unclamping order – PV, infra-hepatic IVC, supra-hepatic IVC, HA and lastly the bile duct OLTx at VAPHS • End of case management – VVB cannula removal – needs purse-string suture – ETT, arterial line and introducer/PAC stay in – Transport with full monitors and 100% FiO2 via ambu to intensive care • Post-op day #1, etc – Extubation and invasive monitor removal depend on graft function, co-existing disease & patient status preoperatively Anesthetic Management of Patients after OLTx • Following successful OLTx, liver synthetic function and metabolic activity return to normal – Lab values normalize – Normal hepatic drug clearance • Circulation no longer hyperdynamic • Oxygenation generally improves, although some anatomic V-Q mismatch may persist Anesthesia after OLTx • No routine lab work (PT/INR/platelets/LFTs) needed for patients with normally functioning grafts • Problems arise from adverse effects (anemia, thrombocytopenia) of and/or drug interactions with chronic immunosuppressive therapy Anesthesia after OLTx • Short-term complications – Technical considerations • Hepatic artery thrombosis (HAT) • Portal vein thrombosis – less common • Bile duct leak – Primary graft non-function – Infection • In these situations refer to previous slides as patients will physiologically once again have ESLD Anesthesia after OLTx • Long-term complications – Chronic kidney disease occurs more frequently in patients with • Diabetes • Hepatitis C – Diabetes occurs more commonly in patients with hep C – Infection Anesthesia after OLTx • Long-term complications – Coronary artery disease • Risk factors – older age at transplant, male sex, post-transplant diabetes or hypertension – Infection – These long-term problems are managed in the usual fashion, irrespective of the OLTx history References • Barash, Paul G, et al. Clinical Anesthesia. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2009. • Miller, Ronald D, et al. Miller’s Anesthesia. 7th ed. Philadelphia: Churchill Livingstone, 2010. • Jaffe, Richard A, et al. Anesthesiologist’s Manual of Surgical Procedures. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2009. • Winter, Peter M., and Yoo Goo Kang. Hepatic Transplantation. New York: Praeger, 1986. References • Murray JF, et al. Circulatory changes in chronic liver disease. Am J Med 1958; 24: 358. • Sharara AI and Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med 2001; 345: 669. • Salerno F, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a metaanalysis of individual patient data. Gastroenterology 2007; 133: 825. • Rodriguez-Roisin R and Krowka MJ. Hepatopulmonary syndrome – a liver-induced lung vascular disorder. N Engl J Med 2008; 358: 2378-87. References • Follo A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495. • Wadei HM, et al. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006; 1: 1066. • Kujovich JL. Hemostatic defects in end stage liver disease. Crit Care Clin 2005; 21: 563-87. • Senzolo M, et al. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006; 12(48): 7725-36. References • Tripodi A and Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-56. • Pugh RNH, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646. • Kamath PS, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464. • Kamath PS and Kim WR. A model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805. References • Mansour A, et al. Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery 1997; 122: 730. • Kang YG, et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987; 66: 766-773. • Albeldawi M, et al. Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transplant 2012; 18: 370-5. • McGuire BM, et al. Long-term management of the liver transplant patient: recommendations for the primary care doctor. Am J Transplant 2009; 9: 1988-2003.